ResearchPod Summary
Achieving a functional cure for HIV remains challenging due to the persistence of latently infected viral reservoirs that evade current antiretroviral therapy (ART). The 'Shock and Kill' strategy aims to reverse this latency using Latency-Reversing Agents (LRAs) to induce viral transcription, rendering the infected cells vulnerable to clearance by the host immune system. This phase 1b/2a clinical trial investigated the safety and efficacy of processed Euphorbia kansui (Kansui)—a traditional Chinese medicine—as a novel LRA in nine HIV-positive male participants who were virally suppressed on ART.
Participants were divided into three cohorts receiving different dosing regimens of processed Kansui: 1 g once daily for 7 days, 1 g twice daily for 7 days, or 1 g once daily for 14 days. Researchers monitored participants using several primary and secondary endpoints, including cell-associated (CA) HIV RNA, plasma viral load, and levels of integrated HIV DNA. The researchers also monitored immune responses by analyzing T-cell subsets and assessing the occurrence of any adverse events during the intervention period.
Kansui showed evidence of successfully reactivating latent HIV in vivo. Approximately 66.7% (6 out of 9) of participants experienced low-level virologic rebound, defined by either increases in CA-HIV RNA or detectable plasma HIV viral load. While integrated HIV DNA levels showed transient fluctuations during the treatment, they returned to baseline by the end of the observation period, indicating that reactivation alone did not lead to a significant long-term reduction in the size of the viral reservoir. The treatment was generally well-tolerated, with only mild adverse events reported (primarily diarrhea); no serious adverse events occurred, suggesting a manageable safety profile for this formulation.
This study provides preliminary clinical evidence that Kansui can act as an LRA in humans. Although it did not clear the HIV reservoir on its own, it contributes to the growing search for potent, safe, and cost-effective agents to activate latent HIV. Future research will need to determine optimal dosing, move beyond simple reactivation to strategies that actively clear the 'shocked' cells, and account for the chemical complexity and variability inherent in herbal medicines.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.